collection
MENU ▼
Read by QxMD icon Read
search

IBD

shared collection
245 papers 500 to 1000 followers
By Jeff Bank Internal Medicine R2 at the University of Utah
https://www.readbyqxmd.com/read/30086261/utility-of-video-capsule-endoscopy-for-longitudinal-monitoring-of-crohn-s-disease-activity-in-the-small-bowel-a-prospective-study
#1
Gil Y Melmed, Marla C Dubinsky, David T Rubin, Mark Fleisher, Shabana F Pasha, Atsushi Sakuraba, Felix Tiongco, Ira Shafran, Ignacio Fernandez-Urien, Bruno Rosa, Neofytos P Papageorgiou, Jonathan A Leighton
BACKGROUND AND AIMS: This prospective, multicenter study evaluated small-bowel capsule endoscopy (CE) for the longitudinal assessment of mucosal inflammation in subjects with Crohn's disease (CD). METHODS: Subjects with known CD underwent clinical evaluation with ileocolonoscopy and CE at baseline and 6-month follow-up. Small-bowel patency was confirmed before CE at both time points. The Simple Endoscopic Score for CD (SES-CD) was used for ileocolonoscopy, and the Lewis score and the Capsule Endoscopy CD Endoscopic Index of Severity (CECDEIS) were used for CE...
August 4, 2018: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/30033449/an-issue-of-control-patient-perspectives-on-use-of-nutritional-interventions-for-ibd
#2
Catalina Berenblum
No abstract text is available yet for this article.
July 23, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/30072777/enteric-infections-are-common-in-patients-with-flares-of-inflammatory-bowel-disease
#3
Jordan E Axelrad, Andrew Joelson, Peter H R Green, Garrett Lawlor, Simon Lichtiger, Ken Cadwell, Benjamin Lebwohl
OBJECTIVES: Few studies have examined the role of non-Clostridium difficile enteric infections in flares of inflammatory bowel disease (IBD). Our objective was to investigate enteric infection detected by multiplex PCR stool testing in patients with IBD. METHODS: We performed a cross-sectional analysis of 9403 patients who underwent 13,231 stool tests with a gastrointestinal pathogen PCR panel during a diarrheal illness from March 2015 to May 2017. Our primary outcome was the presence of an infection...
August 3, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29980848/the-state-of-the-art-on-treatment-of-crohn-s-disease
#4
REVIEW
Hai Yun Shi, Siew Chien Ng
Crohn's disease (CD) is a chronic, progressive, and destructive disease of the gastrointestinal tract. Although its incidence appears to be stable or decreasing in most countries in the North America and Europe, the incidence is rising rapidly in Asian countries. Immunomodulators and biologics are increasingly used to avoid long-term bowel damage and subsequent disability. Therapeutic drug monitoring facilitates optimizing thiopurines and anti-TNFs use. New biologic agents targeting various pathological pathways of CD are blooming in recent years, and the high cost of biologics and expiration of patents for several biologic agents have driven the utility of biosimilars for CD treatment...
July 6, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/30036645/improving-outcomes-in-patients-with-inflammatory-bowel-disease-through-integrated-multi-disciplinary-care-the-future-of-ibd-care
#5
EDITORIAL
Kaci Christian, Raymond K Cross
No abstract text is available yet for this article.
July 20, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/30031174/towards-a-personalized-benefit-risk-balance-for-immunosuppressive-therapy-in-inflammatory-bowel-disease
#6
REVIEW
Laurent Beaugerie, Julien Kirchgesner
Infections, cancers and cardiovascular events are the main events that may be attributable to inflammatory bowel disease (IBD) and/or IBD treatment. Immunosuppressive drugs have been shown to promote immunosuppression-related infections and cancers. Via mucosal healing, immunosuppressive drugs should be able to reduce the incidence of infections related to intestinal lesions, malnutrition, intravenous devices and IBD surgery, and to reduce the incidence of cancers attributable to chronic mucosal inflammation...
July 18, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29988041/increased-use-of-medications-for-erectile-dysfunction-in-men-with-ulcerative-colitis-and-crohn-s-disease-compared-to-men-without-inflammatory-bowel-disease-a-nationwide-cohort-study
#7
S Friedman, B Magnussen, A O'Toole, J Fedder, M D Larsen, B M Nørgård
BACKGROUND: Men with inflammatory bowel disease (IBD) may have decreased sexual function due to factors related to the underlying disease, medication, and/or surgery. We aimed to examine the use of erectile dysfunction (ED) medications in men with IBD. METHODS: This is a nationwide cohort study based on the Danish registries, comprising all men >18 years old with IBD during 1 January 1995 through December 2016. The cohorts included 31,498 men with IBD and 314,980 age-matched men without IBD...
July 10, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29944926/effect-of-accelerated-infliximab-induction-on-short-and-long-term-outcomes-of-acute-severe-ulcerative-colitis-a-retrospective-multi-center-study-and-meta-analysis
#8
Niharika Nalagatla, Katherine Falloon, Gloria Tran, Nienke Z Borren, Danny Avalos, Jay Luther, Francis Colizzo, John Garber, Hamed Khalili, Joanna Melia, Matthew Bohm, Ashwin N Ananthakrishnan
BACKGROUND & AIMS: In patients with acute severe ulcerative colitis (ASUC), standard infliximab induction therapy has modest efficacy. There are limited data on the short-term or long-term efficacy of accelerated infliximab induction therapy for these patients. METHODS: In a retrospective study, we collected data from 213 patients with steroid refractory ASUC who received infliximab rescue therapy at 3 centers, from 2005 through 2017. Patients were classified that received standard therapy (5 mg/kg infliximab at weeks 0, 2, and 6) or accelerated therapy (>5 mg/kg infliximab at shorter intervals)...
June 23, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29935327/loss-of-response-to-vedolizumab-and-ability-of-dose-intensification-to-restore-response-in-patients-with-crohn-s-disease-or-ulcerative-colitis-a-systematic-review-and-meta-analysis
#9
REVIEW
Laurent Peyrin-Biroulet, Silvio Danese, Marjorie Argollo, Lieven Pouillon, Spyros Peppas, Marien Gonzalez-Lorenzo, Theodore Lytras, Stefanos Bonovas
BACKGROUND & AIMS: Vedolizumab is effective and safe for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response to vedolizumab maintenance therapy or whether dose intensification restores response to this drug. METHODS: We searched PubMed, Scopus and conference abstracts (Digestive Disease Week, European Crohn's and Colitis Organization, and United European Gastroenterology Week), through December 2017, for experimental or observational cohort studies of vedolizumab use in adult patients with CD or UC; we identified studies that provided sufficient data to determine the incidence rate of loss of response among initial responders and the ability of dose intensification to restore response...
June 20, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29777041/evolving-role-of-diet-in-the-pathogenesis-and-treatment-of-inflammatory-bowel-diseases
#10
REVIEW
Arie Levine, Rotem Sigall Boneh, Eytan Wine
Recent advances in basic and clinical science over the last 3 years have dramatically altered our appreciation of the role of diet in inflammatory bowel diseases (IBD). The marked increase in incidence of these diseases along with the important role of non-genetic susceptibility among patients with IBD has highlighted that these diseases have a strong environmental component. Progress in the field of microbiome and IBD has demonstrated that microbiome appears to play an important role in pathogenesis, and that diet may in turn impact the composition and functionality of the microbiome...
May 18, 2018: Gut
https://www.readbyqxmd.com/read/29775795/response-to-biologics-delay-progression-of-crohn-s-disease-in-children-but-not-early-surgery
#11
EDITORIAL
Cortney R Ballengee, Subra Kugathasan
No abstract text is available yet for this article.
May 31, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29754190/allergic-and-immunologic-perspectives-of-inflammatory-bowel-disease
#12
REVIEW
Kofi Clarke, Jayakrishna Chintanaboina
Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammatory condition primarily involving the gastrointestinal tract. It includes Crohn's disease (CD), ulcerative colitis (UC), and a less common phenotype-indeterminate colitis. It is thought to result from a complex interplay of environmental, microbial, and host factors including genetic factors, although the exact mechanism is not known. Dietary factors have been shown to play a role in the pathogenesis of IBD and can potentially alter the intestinal microbiota as well as disrupt the immune function in the gut...
May 12, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29759161/outcome-analysis-in-crohn-s-disease-using-endomicroscopy-how-important-and-reliable-is-in-vivo-analysis-of-microscopic-changes
#13
EDITORIAL
Ralf Kiesslich
No abstract text is available yet for this article.
June 2018: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29713028/post-operative-morbidity-and-mortality-of-a-cohort-of-steroid-refractory-acute-severe-ulcerative-colitis-nationwide-multicenter-study-of-the-geteccu-eneida-registry
#14
I Ordás, E Domènech, M Mañosa, V García-Sánchez, E Iglesias-Flores, F Rodríguez-Moranta, L Márquez, O Merino, F Fernández-Bañares, F Gomollón, M Vera, A Gutiérrez, J LLaó, J P Gisbert, M Aguas, L Arias, I Rodríguez-Lago, C Muñoz, N Alcaide, X Calvet, C Rodríguez, M A Montoro, S García, M L De Castro, M Piqueras, L Pareja, J Ribes, J Panés, M Esteve
BACKGROUND: Despite the increased use of rescue medical therapies for steroid refractory acute severe ulcerative colitis, mortality related to this entity still remains high. We aimed to assess the mortality and morbidity related to colectomy and their predictive factors in steroid refractory acute severe ulcerative colitis, and to evaluate the changes in mortality rates, complications, indications of colectomy, and the use of rescue therapy over time. METHODS: We performed a multicenter observational study of patients with steroid refractory acute severe ulcerative colitis requiring colectomy, admitted to 23 Spanish hospitals included in the ENEIDA registry (GETECCU) from 1989 to 2014...
July 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29702298/increased-risk-of-acute-myocardial-infarction-and-heart-failure-in-patients-with-inflammatory-bowel-diseases
#15
Satimai Aniwan, Darrell S Pardi, William J Tremaine, Edward V Loftus
BACKGROUND & AIMS: There are conflicting data as to whether inflammatory bowel diseases (IBDs) increase risk for cardiovascular disease. We sought to examine the risk of acute myocardial infarction (AMI) and heart failure in patients with IBD. METHODS: We identified patients diagnosed with IBD in Olmsted County, Minnesota, from 1980 through 2010 (n = 736). For each patient, 2 individuals without IBD (controls, n = 1472) were randomly selected, matched for age, sex, and index date of disease diagnosis...
April 24, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29702300/budesonide-suppositories-are-effective-and-safe-for-treating-acute-ulcerative-proctitis
#16
Wolfgang Kruis, Viacheslav Neshta, Marina Pesegova, Olga Alekseeva, Pavel Andreev, Oleksii Datsenko, Olena Levchenko, Sayar Abdulkhakov, Yuriy Lozynskyy, Yuriy Mostovoy, Konstantin Soloviev, Andrey E Dorofeyev, Michael Vieth, Michael Stiess, Roland Greinwald, Ralf Mohrbacher, Britta Siegmund
BACKGROUND & AIMS: Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories for proctitis. METHODS: We performed a prospective, double-blind, double-dummy, multicenter trial in 337 patients with active proctitis to compare the efficacies of 4 different suppository treatments...
April 24, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29610508/acg-clinical-guideline-management-of-crohn-s-disease-in-adults
#17
Gary R Lichtenstein, Edward V Loftus, Kim L Isaacs, Miguel D Regueiro, Lauren B Gerson, Bruce E Sands
Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn's disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn's disease has evolved since the last practice guideline was published. These guidelines represent the official practice recommendations of the American College of Gastroenterology and were developed under the auspices of the Practice Parameters Committee for the management of adult patients with Crohn's disease...
April 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29610516/ustekinumab-iv-6-mg-kg-loading-dose-re-induction-improves-clinical-and-endoscopic-response-in-crohn-s-disease-a-case-series
#18
Sunhee Park, Elisabeth Evans, William J Sandborn, Brigid Boland
No abstract text is available yet for this article.
April 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29609069/is-the-objective-of-treatment-for-crohn-s-disease-mucosal-or-transmural-healing
#19
EDITORIAL
Julián Panés, Jordi Rimola
No abstract text is available yet for this article.
July 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29596987/heterogeneity-in-definitions-of-efficacy-and-safety-endpoints-for-clinical-trials-of-crohn-s-disease-a-systematic-review
#20
REVIEW
Christopher Ma, Isra M Hussein, Yousef J Al-Abbar, Remo Panaccione, Richard N Fedorak, Claire E Parker, Tran M Nguyen, Reena Khanna, Corey A Siegel, Laurent Peyrin-Biroulet, Rish K Pai, Niels Vande Casteele, Geert R D'Haens, William J Sandborn, Brian G Feagan, Vipul Jairath
BACKGROUND & AIMS: Endpoints in randomized controlled trials (RCTs) of Crohn's disease (CD) are changing. We performed a systematic review of efficacy and safety outcomes reported in placebo-controlled RCTs of patients with CD. METHODS: We searched the MEDLINE, EMBASE, and the Cochrane Library through March 1, 2017 for placebo-controlled RCTs of adult patients with CD treated with aminosalicylates, immunomodulators, corticosteroids, biologics, and oral small molecules...
March 27, 2018: Clinical Gastroenterology and Hepatology
label_collection
label_collection
2221
1
2
2018-04-02 18:56:30
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"